Welcome to the new AB-Biotics' website. This site is in constant development, following the company's spirit. ABOUT US PRODUCTS LAB SERVICES NEWS INVESTORS CONTACT es ABOUT US Overview History Team Vision & Mision The human microbiota can be regarded as an additional organ per se and performs a wide range of functions, from facilitating the digestion to producing vitamins, modulating the risk of metabolic diseases and helping shape the immune system. However, extensive use of antibiotics and disinfectants in modern societies, as well as dietary changes, have resulted in a significant decline of microbiota diversity. AB-Biotics identified areas where modern lifestyle has had little impact and thus the original microbiota has been preserved. These areas are known to display a low incidence of immune and metabolic disorders, an observation that led to the development of the “hygiene hypothesis”. As a consequence, AB-Biotics conducted several expeditions to isolate Lactic Acid Bacteria Strains from healthy individuals living in those areas, in order to build a strains bank composed of “microbial old friends” whose numbers are declining in the microbiotas of people living in modern societies. Currently, AB-Biotics owns a strains bank with a collection of more than 550 different wild-type strains of human origin sampled from different areas in the world. AB-Biotics was founded by Miquel Angel Bonachera and Sergi Audivert in 2004. Both students at the Universitat Autònoma de Barcelona (UAB), in 2004. The company was started with two technology platforms: — Research and development of probiotics, based on its own collection of 550 strains. — Development of advanced genetic tools for healthcare providers. The AB-BIOTICS team comprises professionals with expertise in different disciplines, including biotechnology, microbiology, genetics, biochemistry, chemistry and bioinformatics, providing us with broad technical knowledge and skills. Vision: AB-Biotics aspires to set a standard in the European biotechnology industry for both Microbiome Modulators and Personalized Medicine. Mision: AB-Biotics strives to improve health by developing products and providing services that help support healthy living and prevent diseases. PRODUCTS Areas Probiotics Genetic tests Probiotics Genetic tests PROBIOTICS THE BEST POSSIBLE STRAIN TO GUARANTEE THE BEST CLINICAL EFFECT READ MORE Cardiometabolic AB-Life Probiotic formula which reduces total cholesterol levels by 12% on average, according to published clinical data. READ MORE AB Life Forte Probiotic formula combining AB-Life strains and Monacolin K to enhance total cholesterol and LDL-cholesterol reduction. READ MORE AB-Life Plus Probiotic formula combining AB-Life strains and an omega-3 source (Alpha-Linolenic Acid) to enhance total cholesterol, LDL-cholesterol and Triglycerides reduction. READ MORE LipiGO Patented weight management solution based on brewer’s yeast cell wall functional extract with selective fat binding properties. READ MORE AB-Fortis Patented micro-encapsulation system that allows to deliver 100% of the iron CDR in a single dose, with high bioavailability and no adverse effects in taste or during the digestion. READ MORE Oral Care AB-Dentalac The first probiotic specifically designed to fight the oral pathogens causing the most common oral diseases: caries, gingivitis and bad breath. READ MORE AB-Dentalac Pro The first probiotic therapy specifically designed for dentists against the most common oral pathogens causing caries, gingivitis and bad breath. READ MORE AB-Dentalac Junior The first probiotic specifically designed to fight the oral pathogens causing the most common oral diseases: caries, gingivitis and bad breath in children. READ MORE AB-Dentisanium Probiotic formula which acts as a shield against caries, preventing the growth of caries-associated bacteria. READ MORE AVANTBISE First line of toothpastes incorporating live patented probiotics. READ MORE Pediatrics AB-Kolicare Probiotic formula for the treatment of infantile colic, which significantly reduces excessive crying in colicky infants according to clinical data. READ MORE AB-Digest Kids Probiotic formula with prebiotics and Zinc for acute treatment and recovery from diarrhea episodes in children. READ MORE IronKid Food supplement which contributes to the normal growth and development of children with a special focus on their mental and cognitive development, containing AB-Fortis (iron), DHA, vitamins and iodine. READ MORE Gastrointestinal Health i3.1 Effective relief of the Irritable Bowel Syndrome (IBS) READ MORE Gynaecology & Urology AB-Intimus Probiotic useful to prevent vaginal infection recurrence, able to survive in an inflamed vaginal mucosa and restore the vaginal ecosystem and a healthy vaginal pH. It can be used in co-therapy treatments with anti-mycotics. Available in different dosage forms (Vaginal tablets, vaginal capsules and oral capsules). READ MORE AB-Intimus Cosmetic Line Foam and Gel for the sensitive area providing effective cleansing and care while preserving acidic pH. READ MORE IronGest Food supplement designed to meet the needs of pregnant women and their babies, containing AB-Fortis (iron), DHA, minerals and vitamins. READ MORE IronLact Food supplement designed to meet the needs of women in lactation period and their babies, containing AB-Fortis (iron), DHA, minerals and vitamins. READ MORE AB-Cyscare Probiotic formula with lactic acid bacteria and cranberry extract for treating and preventing recurrent urinary tract infections (UTI) such as cystitis. READ MORE Dermatology & Immunology AB-Immuno Probiotic formula with a specific functional effect for maintaining digestive health, enhancing systemic immunity and stimulating immunoglobulin production. READ MORE AB-Sakei 65 Probiotic formula for treatment and prevention of atopic dermatitis. READ MORE Probiotics pipeline Hit screening Pre-clinical Industrial scale up Filing patents Clinical Regulatory registers Marketed i3.1 AB-Kolicare AB-Digest Kids AB-Life AB-Life Plus AB-LIFE FORTE AB-Intimus AB-Cyscare AB-Immuno AB-Fortis IronGest IronKid IronLact AB-Sakei 65 AB-Dentalac AB-Dentalac Pro AB-Dentisanium AVANTBISE AB-Intimus Cosmetic Line LipiGO GENETIC TESTS IDENTIFYING THE MOST SUITABLE SOLUTION FOR EACH PATIENT READ MORE Behavioural Health Neuropharmagen A personalized medicine test for behavioral health that helps to identify the most suitable medication for each individual patient by analyzing their DNA. READ MORE Neuropharmagen ADHD A personalized medicine test that helps to identify the most suitable medications prescribed to treat Attention-deficit/hyperactivity disorder (ADHD) and that analyzes genetic factors associated with ADHD etiology and concomitant conditions. READ MORE Pain Medicine Neuropharmagen Analgesia Pharmacogenetic test to improve the efficacy and safety of pain medication by helping predict drug response and the risk of adverse outcomes, by analyzing their DNA. READ MORE Fertility Fertility Test The first genetic test to predict individual response to hormone stimulation treatment in women undergoing an assisted reproduction treatment. READ MORE Urology PCAST & PCA3 PCA3, the Assay for Prostate Cancer and PCAST, the Prostate Cancer Susceptibility Test. READ MORE Genetic tests pipeline Under development Marketed NFG NFG - ADHD Fertility Test PCAST & PCA3 NFG Analgesia LAB SERVICES Areas Personalized Medicine & Genetics Microbiology & Microbiome Modulators. Gallery AB-BIOTICS is actively looking for R&D collaborations with pharmaceutical companies as well as functional food companies. · Personalized Medicine & Genetics AB-BIOTICS Laboratory provides its know-how and state-of-the-art technology in the genetic field to your company. We offer our expertise and skills to develop I+D projects in the field of genomics allowing your company to become more competitive by raising the innovation scope and increasing the added value to your products. READ MORE · Microbiology & Microbiome Modulators AB-BIOTICS offers its expertise in the development of functional ingredients, mainly probiotics for applications in the pharmaceutical industry. We own a strain collection with over 550 wild type strains coming from diverse regions of the world where the human microbiota has not been harmed by modern lifestyle. READ MORE Personalized Medicine & Genetics AB-Biotics laboratory is a private molecular genetics laboratory renowned for its pioneering work in genomic testing and the commercialization of Neuropharmagen, a CNS disorders personalized medicine platform that combines pharmacogenetics with drug pharmacokinetics, drug pharmacodynamics, comorbidity and environmental factors in a single interface for its use in psychiatry and neurology that assures the safest and most appropriates medication for each patient. In addition to we recently implemented genetic tests in the fertility and pain treatment fields. But working in the development of new fields such as Endometriosis, or certain types of specific Oncology testing. Nonetheless AB-BIOTICS is combining its genetics R&D with its microbiome R&D teams in order to develop metagenomic tests to tackle personalized microbiome modulators. We offer a wide range of genomic services which allows us to help our clients select the best solution to meet their business needs. AB-Biotics laboratory has based its strength on its level of equipment with the latest technology available allowing us to reduce costs and to become more competitive. Our staff includes phD scientists expertise in genetics which can guide you through every phase of your project. Moreover, AB-Biotics also offers its expertise on bioinformatics to help get the most of genetic data. By means of its expertise on machine learning algorithms (such as multifactor dimensionality reduction, support vector machines or decision trees), AB-Biotics is able to identify multigene signatures that can display markedly enhanced predictive power compared both to single genes and to multigenic scores based solely on additivity. Machine learning algorithms are better suited to identify predictive signatures from sparse and incomplete datasets than traditional univariate and multivariate statistics, especially when several genetic variants are involved in a given trait and the presence of a variant in one locus can synergize or can nullify the effect of a variant in a second locus. READ MORE Microbiology & Microbiome Modulators. AB-Biotics has developed a wide range of clinically documented probiotics to reduce the risk of cardiovascular disease (AB-LIFE), reduce the burden of gastroinestinal alterations in patients affected by IBD and IBS (I3.1), prevent the recurrence of vaginal Candida infections (AB-INTIMUS), treat infant colic (AB-Colic), displace oral pathogens causing caries, gingivitis and halitosis or bad breath (AB-Dentisanium), etc. During the latest years AB-BIOTICS research activities have been focusing in exhaustive metagenomic analysis of human body’s microbiomes in order to find microbiome modulators aimed at improving the human microbiota to reduce the risk of dysbiosis-related diseases such as Caries or CDI infections. READ MORE NEWS Latest news Archive Press AB·BIOTICS acelera su plan de internacionalización de la biotecnología ‘made in Spain’ La compañía, que cotiza en el MAB desde 2010 inició hace más de una década el registro de patentes y acuerdos comerciales con China, Estados Unidos, Rusia, Turquía y Alemania, entre otros. La compañía ha puesto en marcha con una ampliación de capital de hasta 4.999.998,40 euros aprobada por la Junta de AB·BIOTICS en el pasado mes de junio y comunicada al MAB recientemente. READ MORE Lanzamiento de Neurofarmagen® en Corea del Sur AB-BIOTICS ha cerrado un acuerdo de licencia y distribución de Neurofarmagen®, su test de farmacogenética específico para enfermedades psiquiátricas, con la empresa coreana BL&H Co, dicha empresa ha iniciado la promoción del test en centros de referencia del país y se prevé, además, la realización de un estudio clínico demostrativo para apoyar la promoción del test entre la comunidad médica. READ MORE 16-08-2016 AB·BIOTICS acelera su plan de internacionalización de la biotecnología ‘made in Spain’ La compañía, que cotiza en el MAB desde 2010 inició hace más de una década el registro de patentes y acuerdos comerciales con China, Estados Unidos, Rusia, Turquía y Alemania, entre otros. La compañía ha puesto en marcha con una ampliación de capital de hasta 4.999.998,40 euros aprobada por la Junta de AB·BIOTICS en el pasado mes de junio y comunicada al MAB recientemente. READ MORE 04-09-2015 AB-Biotics alcanza un acuerdo de licencia con Riken Genesis y prepara el lanzamiento en Japón de Neurofarmagen® El mercado de Japón es uno de los más avanzados del mundo en el ámbito de la Genómica y Medicina Personalizada. Tras el actual acuerdo de licencia alcanzado con Riken Genesis se prevé que la firma japonesa inicie de inmediato las actividades de distribución del test y extienda su comercialización por todo el territorio a principios de 2016. READ MORE 05-07-2015 Finalización del proyecto de investigación para el desarrollo de una tecnología biosensora innovadora de genotipado de polimorfismosde un único nucleótido (SNP) El pasado 30 de junio el consorcio formado por la empresa biotecnológica española AB‐BIOTICS y el instituto de investigación IDM de la Universidad Politécnica de Valencia finalizó la participación en el proyecto con la financiación del Ministerio de Ciencia e Innovación, dentro de Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2008‐2011, a través del Programa Innpacto del 2011. READ MORE 15-09-2015 AB-BIOTICS lanza su primer producto en el ámbito de la dermatología en México AB-BIOTICS ha cerrado un acuerdo de distribución en México con la empresa LIFE SENSE para la especialidad probiótica AB-SAKEI PROBIO 65. Este probiótico es un nuevo tratamiento para Dermatitis Atópica y Eczema basado en cepas patentadas de Lactobacillus sakei. READ MORE 03-09-2015 AB-Biotics anuncia un acuerdo de comercialización de AB-Dentalac en EE.UU. AB-Biotics, SA, y Jarrow Formulas, Inc., han anunciado la firma de un acuerdo para la venta del probiótico oral AB-Dentalac a partir de este septiembre en el mercado de EE.UU, alianza que va a permitir la entrada de AB-Biotics en el mercado estadounidense READ MORE 02-06-2015 Lanzado el primer producto de AB- BIOTICS en Australia de la mano de MYLAND AB-LIFE fue aprobado por las autoridades Australianas como medicamento para el control del colesterol en Enero de este año. Mylan EPD lanzó en junio el producto bajo la marca Enliva, en el Congreso Anual de Farmacéuticos de Australia. READ MORE 1 2 3 4 5 6 7 8 9 10 11 For press releases contact us info@ab-biotics.com 902 903 844 / + 34 972 183 421 Descargar presskit en PDF INVESTORS Info general Info económico-financiera Agenda del inversor Información general Presentaciones Acción de capital social Estatutos sociales Reglamento interno de conducta Reglamento del Consejo de Administración DIM DAM julio 2011 DAM noviembre 2011 DAM 2012 DAM agosto 2013 DAM agosto 2016 Relevant information and others of interest to investors 28/09/2016 Hecho Relevante: Resultado de la ampliacion de capital READ MORE 22/09/2016 Hecho Relevante: Obtención de crédito. Actualización de información sobre préstamo READ MORE 31/08/2016 Hecho Relevante: Concesión de la patente para el AB-Fortis en Chile READ MORE 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 Info. Económico-Financiera Información 2015 - Anual Información 2015 - Semestral Información 2014 - Anual Información 2014 - Semestral Información 2013 - Anual Información 2013 - Semestral Información 2012 - Anual Información 2012 - Semestral Información 2011 - Anual Información 2011 - Semestral Información 2010 - Anual Información 2010 - Semestral Evolución de la Acción Cotización AB-BIOTICS Agenda del inversor 20/05/2016 Propuesta de acuerdos a adoptar en la Junta de Accionistas de AB-BIOTICS, S.A. 20/05/2016 Informe del Consejo de Administración de AB - BIOTICS, S.A. 20/05/2016 Informe del Consejo de Administración de AB-BIOTICS, S.A. 28/05/2012 Información sobre la propuesta de nombramiento de un nuevo miembro para el consejo de administración de AB-BIOTICS 27/05/2012 Informe justificativo de la propuesta de delegación en el Consejo de la facultad para emitir obligaciones, bonos, participaciones preferentes y demás valores de renta fija o instrumentos de deuda 27/05/2012 Informe justificativo de la propuesta de delegación en el Consejo de Administración de la facultad de ampliar el capital social 23/09/2011 Modelo Comunicación Distribución Participaciones AB Therapeutics - Persona Jurídica 23/09/2011 Modelo Comunicación Distribución Participaciones AB Therapeutics - Persona Física 23/09/2011 Anuncio en el BORME sobre la distribución de parte de la prima de emisión 05/04/2011 Nota informativa sobre la Junta Extraordinaria de Accionistas del próximo 11 de abril de 2011 CONTACT Contact CONTACT DETAILS AB-BIOTICS, S.A. Esade Creapolis Av. de la Torre Blanca, 57 – Desp. 3B06 08172 St. Cugat del Vallès (Barcelona) Tel. 902 903 844 ·GENERAL INFORMATION - info@ab-biotics.com ·ADMINISTRATIVE DEPARTMENT - admin@ab-biotics.com ·BUSINESS DEVELOPMENT - licensing@ab-biotics.com ·CUSTOMER'S ORDERS - orders@ab-biotics.com ·INVESTORS - investors@ab-biotics.com ·HUMAN RESOURCES - rrhh@ab-biotics.com ·QUALITY DEPARTMENT - quality@ab-biotics.com ·PHARMACOVIGILANCE - pharmacovigilance@ab-biotics.com Head Offices ESADECREAPOLIS – Sant Cugat del Vallès Laboratory in Parc Científic UdG - Girona Headquarters EUREKA, Parc de Recerca UAB – Bellaterra. 2016 © AB Biotics | All Rights Reserved | Edifici Eureka - Campus UAB - 08193 Bellaterra (Barcelona) | info@ab-biotics.com Legal